Affirms Full Year 2025 Guidance
Acadia Healthcare Company, Inc. ("Acadia" or the "Company") (NASDAQ:ACHC) today announced financial results for the first quarter ended March 31, 2025.
First Quarter 2025 Highlights
- Revenue totaled $770.5 million, compared with $768.1 million for the first quarter of 2024
- Same facility revenue increased 2.1% compared with the first quarter of 2024, including an increase in patient days of 2.2%
- Same facility revenue and patient day growth both included an unfavorable year-over-year impact from the leap year of approximately 1.1%
- Net income attributable to Acadia totaled $8.4 million, or $0.09 per diluted share
- Adjusted income attributable to Acadia totaled $36.9 million, or $0.40 per diluted share.
- Adjusted EBITDA totaled $134.2 million, including a previously disclosed $5 million year-over-year impact related to the decision to close one facility during the first quarter
- Continued progress on the execution of the Company's growth strategy, with the addition of 378 newly licensed beds during the first quarter, including 90 beds to existing facilities and 288 beds from newly constructed facilities.
Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 9.
First Quarter Results
Chris Hunter, Chief Executive Officer of Acadia, remarked, "We are pleased to deliver first quarter results for both revenue and Adjusted EBITDA in line with our respective outlook ranges, with Adjusted EBITDA coming in at the high end of our expectations for the quarter. This year is setting up to be the largest bed expansion year in Acadia's history, building upon our record-breaking bed additions in 2024. We are well-positioned to continue expanding access and providing specialized care and treatment to an underserved patient population with complex needs. With our patient-centric approach and strong focus on clinical quality, Acadia is committed to expanding access to care and treatment to all those requiring help. We are proud of the extraordinary work of our dedicated team of employees and clinicians who are meeting this need every day by providing safe, quality patient care for those seeking treatment for mental health and substance use issues. Together, we look forward to the opportunities ahead for Acadia in 2025."
Strategic Investments for Long-Term Growth
During the first quarter of 2025, the Company continued to make progress in meeting its strategic growth objectives. This includes the addition of 90 beds to existing facilities and 288 beds to new facilities, for a total of 378 newly licensed beds in the first quarter.
In addition, Acadia added seven new comprehensive treatment centers ("CTCs"), extending the Company's market reach to 170 CTCs across 33 states, treating approximately 74,000 patients daily in this critical area of care.
During the first quarter, the Company commenced operations at two new facilities, including a de novo facility in North Port, Florida, and a joint venture hospital in partnership with Henry Ford Health, in West Bloomfield, Michigan. Acadia has 21 joint venture partnerships for 22 hospitals, with 13 hospitals already in operation and nine additional hospitals expected to open in the coming years.
Cash and Liquidity
Maintaining a strong financial position to support growth investments and disciplined capital allocation are top priorities for Acadia. As of March 31, 2025, the Company had $91.2 million in cash and cash equivalents and $901.6 million available under its $1 billion revolving credit facility.
Share Repurchase Authorization
On February 27, 2025, Acadia announced that its Board of Directors authorized a share repurchase program for up to $300 million of the Company's outstanding common stock. Repurchases under the share repurchase program may be made from time to time, subject to market conditions and management's discretion, in the open market or in privately negotiated transactions. The authorization for the repurchase program has no expiration date.
The Company repurchased 1,602,688 shares for a total of $47.3 million during the first quarter of 2025.
2025 Financial Guidance
Acadia today affirmed its previously announced financial guidance for 2025, as follows:
|
2025 Guidance Range |
Revenue |
$3.3 to $3.4 billion |
Adjusted EBITDA |
$675 to $725 million |
Adjusted earnings per diluted share |
$2.50 to $2.80 |
Interest expense |
$130 to $140 million |
Tax rate |
25% to 26% |
Depreciation and amortization expense |
$175 to $185 million |
Stock compensation expense |
$45 to $50 million |
Operating cash flows |
$460 to $510 million |
Expansion capital expenditures |
$525 to $575 million |
Maintenance and IT capital expenditures |
$105 to $115 million |
Total bed additions |
800 to 1,000 beds |
The Company's full-year guidance includes the following assumptions:
- Same-facility volume growth in the low-to-mid-single digits.
- Same-facility revenue per patient day growth in the low single digits.
- A year-over-year increase in startup losses of approximately $25 million, totaling approximately $50-$55 million in losses for the full year 2025 related to newly opened facilities.
- The Company continues to expect a net increase in Medicaid supplemental payments of $0 to $15 million for the full year 2025, inclusive of the new Tennessee program.
The Company's guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.
Conference Call
Acadia will hold a conference call to discuss its first quarter financial results at 7:30 a.m. Central Time/8:30 a.m. Eastern Time on Tuesday, May 13, 2025. A live webcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website. The webcast of the conference call will be available for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of March 31, 2025, Acadia operated a network of 270 behavioral healthcare facilities with approximately 12,000 beds in 39 states and Puerto Rico. With approximately 25,500 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Forward-Looking Information
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements related to our strategy, growth, anticipated operating results for future periods and our share repurchase program. Generally, words such as "may," "will," "should," "could," "anticipate," "expect," "intend," "estimate," "plan," "continue," and "believe" or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia's ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia's periodic reports and other filings with the SEC.
Share Repurchase Authorization Disclaimer
Acadia's share repurchase program permits the Company to make repurchases on a discretionary basis as determined by management, subject to market conditions, applicable legal requirements, available liquidity, compliance with the Company's debt agreements, and other appropriate factors. Repurchases under the share repurchase program are to be made through open market or privately negotiated transactions and may be made pursuant to plans entered into in accordance with Rule 10b5-1 and/or Rule 10b-18 of the Exchange Act. The share repurchase program does not have a termination date, does not obligate Acadia to acquire any particular amount of common stock, and may be modified, extended, suspended, or discontinued by the Company's Board of Directors at any time without prior notice. No assurance can be given that any particular amount of common stock will be repurchased.
Acadia Healthcare Company, Inc. |
||||||||
Condensed Consolidated Statements of Operations |
||||||||
(Unaudited) |
||||||||
Three Months Ended March 31, |
||||||||
|
2025 |
|
|
|
2024 |
|
||
(In thousands, except per share amounts) |
||||||||
| Revenue | $ |
770,505 |
|
$ |
768,051 |
|
||
| Salaries, wages and benefits (including equity-based compensation expense of $8,677 and $8,678, respectively) |
|
445,271 |
|
|
417,523 |
|
||
| Professional fees |
|
45,707 |
|
|
45,688 |
|
||
| Supplies |
|
28,342 |
|
|
26,652 |
|
||
| Rents and leases |
|
11,656 |
|
|
11,863 |
|
||
| Other operating expenses |
|
114,002 |
|
|
101,073 |
|
||
| Depreciation and amortization |
|
47,032 |
|
|
36,347 |
|
||
| Interest expense, net |
|
29,182 |
|
|
27,214 |
|
||
| Debt extinguishment costs |
|
1,269 |
|
|
— |
|
||
| Legal settlements expense |
|
3,504 |
|
|
— |
|
||
| Transaction, legal and other costs |
|
31,072 |
|
|
2,847 |
|
||
| Total expenses |
|
757,037 |
|
|
669,207 |
|
||
| Income before income taxes |
|
13,468 |
|
|
98,844 |
|
||
| Provision for income taxes |
|
4,404 |
|
|
20,074 |
|
||
| Net income |
|
9,064 |
|
|
78,770 |
|
||
| Net income attributable to noncontrolling interests |
|
(690 |
) |
|
(2,387 |
) |
||
| Net income attributable to Acadia Healthcare Company, Inc. | $ |
8,374 |
|
$ |
76,383 |
|
||
| Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: | ||||||||
| Basic | $ |
0.09 |
|
$ |
0.84 |
|
||
| Diluted | $ |
0.09 |
|
$ |
0.83 |
|
||
| Weighted-average shares outstanding: | ||||||||
| Basic |
|
91,654 |
|
|
91,363 |
|
||
| Diluted |
|
92,038 |
|
|
92,010 |
|
||
Acadia Healthcare Company, Inc. |
||||||
Condensed Consolidated Balance Sheets |
||||||
(Unaudited) |
||||||
March 31, |
|
December 31, |
||||
2025 |
|
2024 |
||||
(In thousands) |
||||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ |
91,236 |
$ |
76,305 |
||
| Accounts receivable, net |
|
396,632 |
|
365,339 |
||
| Other current assets |
|
151,082 |
|
135,848 |
||
| Total current assets |
|
638,950 |
|
577,492 |
||
| Property and equipment, net |
|
2,955,952 |
|
2,853,193 |
||
| Goodwill |
|
2,276,368 |
|
2,264,851 |
||
| Intangible assets, net |
|
78,825 |
|
70,003 |
||
| Deferred tax assets |
|
23,179 |
|
20,964 |
||
| Operating lease right-of-use assets |
|
120,701 |
|
118,369 |
||
| Other assets |
|
53,623 |
|
52,043 |
||
| Total assets | $ |
6,147,598 |
$ |
5,956,915 |
||
| LIABILITIES AND EQUITY | ||||||
| Current liabilities: | ||||||
| Current portion of long-term debt | $ |
16,250 |
$ |
76,816 |
||
| Accounts payable |
|
204,012 |
|
232,704 |
||
| Accrued salaries and benefits |
|
140,125 |
|
155,426 |
||
| Current portion of operating lease liabilities |
|
24,816 |
|
25,462 |
||
| Other accrued liabilities |
|
88,148 |
|
87,511 |
||
| Total current liabilities |
|
473,351 |
|
577,919 |
||
| Long-term debt |
|
2,184,293 |
|
1,880,093 |
||
| Deferred tax liabilities |
|
80,540 |
|
83,946 |
||
| Operating lease liabilities |
|
101,314 |
|
101,828 |
||
| Other liabilities |
|
134,122 |
|
122,298 |
||
| Total liabilities |
|
2,973,620 |
|
2,766,084 |
||
| Redeemable noncontrolling interests |
|
132,420 |
|
117,116 |
||
| Equity: | ||||||
| Common stock |
|
904 |
|
918 |
||
| Additional paid-in capital |
|
2,692,203 |
|
2,685,464 |
||
| Retained earnings |
|
348,451 |
|
387,333 |
||
| Total equity |
|
3,041,558 |
|
3,073,715 |
||
| Total liabilities and equity | $ |
6,147,598 |
$ |
5,956,915 |
||
Acadia Healthcare Company, Inc. |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(Unaudited) |
||||||||
Three Months Ended March 31, |
||||||||
|
2025 |
|
|
|
2024 |
|
||
(In thousands) |
||||||||
| Operating activities: | ||||||||
| Net income | $ |
9,064 |
|
$ |
78,770 |
|
||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization |
|
47,032 |
|
|
36,347 |
|
||
| Amortization of debt issuance costs |
|
1,056 |
|
|
1,016 |
|
||
| Equity-based compensation expense |
|
8,677 |
|
|
8,678 |
|
||
| Deferred income taxes |
|
(5,621 |
) |
|
17,476 |
|
||
| Debt extinguishment costs |
|
1,269 |
|
|
— |
|
||
| Legal settlements expense |
|
3,504 |
|
|
— |
|
||
| Other |
|
73 |
|
|
(4,094 |
) |
||
| Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||
| Accounts receivable, net |
|
(30,993 |
) |
|
(22,930 |
) |
||
| Other current assets |
|
(9,019 |
) |
|
(15,629 |
) |
||
| Other assets |
|
(1,214 |
) |
|
696 |
|
||
| Accounts payable and other accrued liabilities |
|
(9,242 |
) |
|
(403,340 |
) |
||
| Accrued salaries and benefits |
|
(19,801 |
) |
|
(25,024 |
) |
||
| Other liabilities |
|
16,692 |
|
|
6,749 |
|
||
| Net cash provided by (used in) operating activities |
|
11,477 |
|
|
(321,285 |
) |
||
| Investing activities: | ||||||||
| Cash paid for acquisitions, net of cash acquired |
|
(8,594 |
) |
|
(50,353 |
) |
||
| Cash paid for capital expenditures |
|
(174,631 |
) |
|
(142,410 |
) |
||
| Proceeds from sale of property and equipment |
|
43 |
|
|
9,056 |
|
||
| Other |
|
(56 |
) |
|
(907 |
) |
||
| Net cash used in investing activities |
|
(183,238 |
) |
|
(184,614 |
) |
||
| Financing activities: | ||||||||
| Borrowings on long-term debt |
|
1,200,000 |
|
|
350,000 |
|
||
| Borrowings on revolving credit facility |
|
760,000 |
|
|
160,000 |
|
||
| Principal payments on revolving credit facility |
|
(1,035,000 |
) |
|
(15,000 |
) |
||
| Principal payments on long-term debt |
|
— |
|
|
(10,242 |
) |
||
| Repayment of long-term debt |
|
(670,856 |
) |
|
— |
|
||
| Payment of debt issuance costs |
|
(18,615 |
) |
|
(1,518 |
) |
||
| Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises |
|
(1,936 |
) |
|
(1,013 |
) |
||
| Repurchase of common stock |
|
(46,880 |
) |
|
— |
|
||
| Contributions from noncontrolling partners in joint ventures |
|
— |
|
|
2,280 |
|
||
| Distributions to noncontrolling partners in joint ventures |
|
— |
|
|
(1,020 |
) |
||
| Other |
|
(21 |
) |
|
(358 |
) |
||
| Net cash provided by financing activities |
|
186,692 |
|
|
483,129 |
|
||
| Net increase (decrease) in cash and cash equivalents |
|
14,931 |
|
|
(22,770 |
) |
||
| Cash and cash equivalents at beginning of the period |
|
76,305 |
|
|
100,073 |
|
||
| Cash and cash equivalents at end of the period | $ |
91,236 |
|
$ |
77,303 |
|
||
| Effect of acquisitions: | ||||||||
| Assets acquired, excluding cash | $ |
19,768 |
|
$ |
55,309 |
|
||
| Liabilities assumed |
|
(300 |
) |
|
(3,456 |
) |
||
| Contingent consideration issued in connection with an acquisition |
|
— |
|
|
(1,500 |
) |
||
| Redeemable noncontrolling interest resulting from an acquisition |
|
(10,874 |
) |
|
— |
|
||
| Cash paid for acquisitions, net of cash acquired | $ |
8,594 |
|
$ |
50,353 |
|
||
Acadia Healthcare Company, Inc. |
|||||||||
Operating Statistics (1) |
|||||||||
(Unaudited, $ in thousands except per Patient Day metrics) |
|||||||||
Three Months Ended March 31, |
|||||||||
2025 |
|
2024 |
|
% Change |
|||||
| Same Facility Results (2) | |||||||||
| Revenue | $ |
759,697 |
$ |
744,422 |
2.1 |
% |
|||
| Patient Days |
|
763,958 |
|
747,394 |
2.2 |
% |
|||
| Admissions |
|
48,507 |
|
47,503 |
2.1 |
% |
|||
| Average Length of Stay (3) |
|
15.7 |
|
15.7 |
0.1 |
% |
|||
| Revenue per Patient Day | $ |
994 |
$ |
996 |
-0.2 |
% |
|||
| Adjusted EBITDA | $ |
191,605 |
$ |
210,579 |
-9.0 |
% |
|||
| Total Facility Results | |||||||||
| Revenue | $ |
770,505 |
$ |
768,051 |
0.3 |
% |
|||
| Patient Days |
|
774,933 |
|
768,678 |
0.8 |
% |
|||
| Admissions |
|
49,683 |
|
49,058 |
1.3 |
% |
|||
| Average Length of Stay (3) |
|
15.6 |
|
15.7 |
-0.5 |
% |
|||
| Revenue per Patient Day | $ |
994 |
$ |
999 |
-0.5 |
% |
|||
| Adjusted EBITDA | $ |
172,361 |
$ |
210,926 |
-18.3 |
% |
|||
| (1) Total facility and same facility results may not be indicative of the overall performance of our business and should not be considered as alternatives for net income or any other performance measures in accordance with GAAP (as defined herein). | |||||||||
| (2) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services. | |||||||||
| (3) Average length of stay is defined as patient days divided by admissions. | |||||||||
Acadia Healthcare Company, Inc. |
||||||||
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA and Same Facility Adjusted EBITDA |
||||||||
(Unaudited) |
||||||||
Three Months Ended March 31, |
||||||||
|
2025 |
|
|
|
2024 |
|
||
(in thousands) |
||||||||
| Net income attributable to Acadia Healthcare Company, Inc. | $ |
8,374 |
|
$ |
76,383 |
|
||
| Net income attributable to noncontrolling interests |
|
690 |
|
|
2,387 |
|
||
| Provision for income taxes |
|
4,404 |
|
|
20,074 |
|
||
| Interest expense, net |
|
29,182 |
|
|
27,214 |
|
||
| Depreciation and amortization |
|
47,032 |
|
|
36,347 |
|
||
| EBITDA |
|
89,682 |
|
|
162,405 |
|
||
| Adjustments: | ||||||||
| Equity-based compensation expense (a) |
|
8,677 |
|
|
8,678 |
|
||
| Transaction, legal and other costs (b) |
|
31,072 |
|
|
2,847 |
|
||
| Debt extinguishment costs (c) |
|
1,269 |
|
|
— |
|
||
| Legal settlements expense (d) |
|
3,504 |
|
|
— |
|
||
| Adjusted EBITDA | $ |
134,204 |
|
$ |
173,930 |
|
||
| Corporate general and administrative costs (e) |
|
(38,157 |
) |
|
(36,996 |
) |
||
| Total Facility Adjusted EBITDA |
|
172,361 |
|
|
210,926 |
|
||
| De novos, acquisitions, and closed facilities (f) |
|
(19,244 |
) |
|
347 |
|
||
| Same Facility Adjusted EBITDA | $ |
191,605 |
|
$ |
210,579 |
|
||
| See footnotes on pages 11-12. | ||||||||
Acadia Healthcare Company, Inc. |
||||||
Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to |
||||||
Adjusted Income Attributable to Acadia Healthcare Company, Inc. |
||||||
(Unaudited) |
||||||
Three Months Ended March 31, |
||||||
2025 |
|
2024 |
||||
(in thousands, except per share amounts) |
||||||
| Net income attributable to Acadia Healthcare Company, Inc. | $ |
8,374 |
$ |
76,383 |
||
| Adjustments to income: | ||||||
| Transaction, legal and other costs (b) |
|
31,072 |
|
2,847 |
||
| Debt extinguishment costs (c) |
|
1,269 |
|
— |
||
| Legal settlements expense (d) |
|
3,504 |
|
— |
||
| Provision for income taxes |
|
4,404 |
|
20,074 |
||
Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. |
|
48,623 |
|
99,304 |
||
| Income tax effect of adjustments to income (g) |
|
11,694 |
|
22,011 |
||
| Adjusted income attributable to Acadia Healthcare Company, Inc. |
|
36,929 |
|
77,293 |
||
| Weighted-average shares outstanding - diluted |
|
92,038 |
|
92,010 |
||
| Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share | $ |
0.40 |
$ |
0.84 |
||
| See footnotes on pages 11-12. | ||||||
| Acadia Healthcare Company, Inc. |
| Footnotes |
| We have included certain financial measures in this press release, including those listed below, which are "non-GAAP financial measures" as defined under the rules and regulations promulgated by the SEC. These non-GAAP financial measures include, and are defined, as follows: |
| • EBITDA: net income attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization. |
| • Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, debt extinguishment and legal settlements expense. |
| • Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, debt extinguishment, legal settlements expense and provision for income taxes. |
| • Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income. |
| • Total facility adjusted EBITDA: Adjusted EBITDA adjusted for general and administrative costs related to our corporate functions. General and administrative costs directly related to the facilities are included in total facility results. |
| • Same facility adjusted EBITDA: Adjusted EBITDA for facilities and services to those facilities operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired, divested or removed from service during the current or prior year. |
| The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States ("GAAP"). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company's historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. |
| Total facility results include operating results for all of our facilities and services but exclude general and administrative costs related to our corporate functions. Such costs related to our corporate functions include, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. General and administrative costs directly related to the facilities are included in facility results. Such costs directly related to our facilities include, amongst others, labor at the facility level, insurance, including property, professional, legal and general liability insurance, hospital supplies, including medication, utilities and food service, and general maintenance costs for the facility. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Note that total facility costs include those related to new facilities and the cost of closure and run-out costs related to facilities we have closed. We believe that providing results on a total facility basis is helpful to our investors as a measure of our financial and operating performance because it neutralizes the impact of corporate-level items that do not arise out of our core operations at our facilities. |
| Same facility results include operating results only for facilities and services operated in both the current and prior year. These metrics exclude the operating results associated with facilities under operation for less than one year and facilities acquired during the current or prior year, as well as facilities divested or removed from service. We believe that providing results on a same facility basis is helpful to investors because it neutralizes the impact of new facilities that are in early stages of operation and facilities that we no longer operate, each of which may distort investors' understanding of the Company's underlying performance at our existing and continuing facilities. Further, we believe that providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities. For these reasons, we believe that same facility results are particularly useful during periods of significant expansion or contraction. |
| Total facility results reflect adjustments that are intended to provide the specific presentation described above, and same facility results reflect adjustments that may be irregular in timing from period to period related to newly opened or acquired facilities or facilities that we no longer operate, and may omit certain results that investors may view as important. Total facility and same facility results may therefore not be indicative of the overall performance of our business and should be not be considered as alternatives for net income or any other performance measures derived in accordance with GAAP. |
| The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. |
Acadia Healthcare Company, Inc. |
|||||||||
Footnotes (continued) |
|||||||||
| (a) Represents the equity-based compensation expense of Acadia. Equity-based compensation expense is excluded from Adjusted EBITDA because Acadia believes that the cost of equity awards granted to employees does not contribute to the earnings potentially available for distributions to its equity holders or reinvestment into its business. | |||||||||
| (b) Represents transaction, legal, and other costs incurred by Acadia primarily related to the following categories: (1) government investigations; (2) termination and restructuring costs; (3) legal, accounting, and other acquisition-related costs; and (4) management transition costs. Government investigations include legal fees and settlement costs related to certain litigation. Termination and restructuring costs include costs, net of gains, incurred related to the closure and disposition of certain facilities or contract amendments. Legal, accounting and other acquisition-related costs include costs incurred for the development of new facilities ($0.9 million and $0.6 million for the three months ended March 31, 2025 and 2024, respectively); legal and settlement costs incurred related to certain litigation not included in Government Investigations ($(3.0) million and $4.0 million for the three months ended March 31, 2025 and 2024, respectively); and direct costs associated with acquisitions ($0.2 million for the three months ended March 31, 2024). Management transition costs include certain costs associated with the transition of the leadership team, including the design and implementation of the revised organizational structure. Management transition costs incurred with the transition of our Chief Executive Officer beginning in the first quarter of 2022 have concluded. The table below quantifies each of the components of transaction, legal and other costs for the periods presented. Such transaction, legal and other costs are excluded from Adjusted EBITDA because Acadia believes that the nature, size, and number of these costs can vary dramatically from period to period and between Acadia and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult. | |||||||||
Three Months Ended March 31, |
|||||||||
|
2025 |
|
|
|
2024 |
|
|||
(in thousands) |
|||||||||
| Government investigations | $ |
31,011 |
|
$ |
481 |
|
|||
| Termination and restructuring costs |
|
2,166 |
|
|
(3,400 |
) |
|||
| Legal, accounting and other acquisition-related costs |
|
(2,105 |
) |
|
4,757 |
|
|||
| Management transition costs |
|
— |
|
|
1,009 |
|
|||
| Transaction, legal, and other costs | $ |
31,072 |
|
$ |
2,847 |
|
|||
| (c) Represents debt extinguishment costs recorded during the first quarter of 2025 in connection with the refinancing of the prior credit facility. Debt extinguishment is excluded from Adjusted EBITDA because Acadia believes that this expense is unrelated to Acadia's day-to-day business operations and not indicative of Acadia's ongoing operating results. | |||||||||
| (d) Represents legal settlements expense related to costs associated with the Desert Hills litigation. Legal settlements expense is excluded from Adjusted EBITDA because Acadia believes that this expense is unrelated to Acadia's day-to-day business operations and not indicative of Acadia's ongoing operating results. | |||||||||
| (e) Represents general and administrative costs related to our corporate functions, including, amongst others, costs for accounting and finance, information systems, human resources, legal and operational and executive leadership. We determine which general and administrative costs to exclude and include in total facility results by ensuring those costs directly associated with facility operations are captured at the facility level for reporting. Corporate general and administrative costs are excluded to present Total Facility Adjusted EBITDA because we believe that providing results on a total facility basis is helpful to our investors as a measure of the financial and operating performance of our core operations at our facilities. | |||||||||
| (f) Represents the portion of EBITDA for the periods presented attributable to de novos and acquired facilities in operation for less than one year and facilities closed during such period. De novos are newly developed facilities built by Acadia or with a joint venture partner. Such amounts are excluded from Adjusted EBITDA to present Same Facility Adjusted EBITDA because we believe providing same facility information is helpful to our investors as a measure of the financial and operating performance of our existing and continuing facilities on a comparable basis, and same facility results provide investors with information useful in understanding underlying organic growth in such facilities. | |||||||||
| (g) Represents the income tax effect of adjustments to income based on tax rates of 24.1% and 22.2% for the three months ended March 31, 2025 and 2024, respectively. We believe excluding the income tax effect of adjustments to income assists investors in understanding the tax provision associated with those adjustments and the effect on net income. | |||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20250512395602/en/
Investor Contact:
Patrick Feeley
Senior Vice President, Investor Relations
(615) 861-6000